Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 127

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 8
Chunk 127
---
5 years after expiring of any exclusivity, or price, reimbursement protection. The expected expiry date
of the last-to-expire patent is 2041. In addition, the agreement may be terminated by either party for cause or by Radiopharm at will
by giving 90 days’ written notice.

Amended License Agreement with NanoMab

In August 2021, Radiopharm
entered into an amendment to the License Agreement with NanoMab for the additional licensing to Radiopharm of the anti-PDL-1 patent relating
to nanobodies and coding sequences.

In addition to the amounts
payable under the first agreement, Radiopharm must pay NanoMab an upfront payment up to US$2.0 million. Additionally, Radiopharm is required
to pay NanoMab up to US$6.5 million upon the achievement of the several development milestones in connection with the PDL-1 therapeutic
product.

IP Assignment Agreement with NanoMab and NanoMab UK

In January 2022, Radiopharm
entered into an assignment agreement with NanoMab and NanoMab (UK) Limited (“ NanoMab UK”) pursuant to which NanoMab and NanoMab
UK assigned their entire worldwide legal and beneficial rights in the Anti-HER2 Nanobody, anti-TROP2 Nanobody and anti-PTK-7 Nanobody
patents and know-how (which includes pre-clinical and proof-of-concept data) to Radiopharm.

As consideration for the assignment,
Radiopharm shall pay to NanoMab ordinary shares equivalent to US$0.5 million based of ordinary shares.

License Agreement with TRIMT

In July 2021, Radiopharm entered
into an exclusive license agreement with TRIMT GmbH (“ TRIMT”) for the68Ga-Trivehexin technology. Under the terms
of the agreement, TRIMT granted to Radiopharm the exclusive royalty-bearing and sublicensable right and license to the patent rights regarding
Cyclic peptides and their conjugates for addressing alpha-v-beta-6-integrin in vivo and any other associated patent rights for all diagnostic
and radiotherapeutic applications in the United States, Japan, Hong Kong, China and Australia. Radiopharm was also granted a non-exclusive,
cost-free right and license for non-commercial research purposes to specific radionuclides for all diagnostic and radiotherapeutic applications.
TRIMT retained rights with respect to the patents subject of the